11 hrs ago
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
Bristol-Myers Squibb and Ono Pharmaceutical signed a collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea, and Taiwan.
Sat Jul 26, 2014
Bristol-Myers Squibb Given "Neutral" Rating at Zacks
's stock had its "neutral" rating reiterated by Zacks in a report issued on Friday.
Fri Jul 25, 2014
Why Bristol-Myers Squibb Loses Out Against This Rival
We pitch two companies from the GICS sector 'health care distributors and services', Bristol-Myers Squibb and Express Scripts, against one another in the latest instalment of our Head-To-Head series.
BioMed Realty And Bristol-Myers Squibb Company Sign Lease To Expand ...
BioMed Realty And Bristol-Myers Squibb Company Sign Lease To Expand Relationship To 194,100 Square Feet At Woodside Technology Park In Redwood City, California /PRNewswire/ -- BioMed Realty Trust, Inc. today announced that Bristol-Myers Squibb has signed a ten-year lease for approximately 61,000 square feet of additional laboratory and office space ... (more)
Thu Jul 24, 2014
Thursday Morning Earnings Reports
American Airlines Group reported its Q2 earnings with EPS of $1.98 compared to analyst estimates of $1.95 and revenue of $11.36 billion compared to estimates of $11.33 billion.
Bristol-Myers Squibb Company Appoints As India Country Head
Bristol-Myers Squibb India appointed Jitendra Tyagi as the BMS India country head.
Wed Jul 23, 2014
Innate Pharma : Completion of target enrollment in the phase II EffiKIR trial
Innate Pharma SA , the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announced completion of target enrollment in the EffiKIR trial with 150 patients randomized.
Customer Interaction Solutions
Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce...
Ono Pharmaceutical Co., Ltd. have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.
The Motley Fool
Earnings Preview: Bristol-Myers Squibb and Celgene Corporation
Most health care stocks have been experiencing a roller coaster ride so far this year.
Forbes Earnings Preview: Bristol Myers Squibb
Bristol Myers Squibb reports its second-quarter earnings on Thursday, July 24, 2014, and the consensus earnings per share estimate is 45 cents per share.
Tue Jul 22, 2014
Bristol-Myers Squibb Given Average Rating of "Buy" by Analysts
Bristol-Myers Squibb has been given a consensus rating of "Buy" by the seventeen analysts that are presently covering the stock, Analyst Ratings News reports .
Thu Jul 17, 2014
Drug Roundup - July 17, 2014
There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve.
Bristol-Myers Squibb Company And Pfizer Inc. Announce Enrollment Of...
Bristol-Myers Squibb Company And Pfizer Inc. Announce Enrollment Of First Patient In Phase IV EMANATE Trial To Assess Effectiveness And Safety Of Eliquis In Patients With NVAF Undergoing Cardioversion PRINCETON, N.J. & NEW YORK-- --Bristol-Myers Squibb Company and Pfizer Inc. today announced that the first patient has been enrolled into a Phase IV ... (more)
Press release distribution, EDGAR filing, XBRL, regulatory filings
Net income for the quarter ended June 30, 2014 was $3,873,000 or $1.82 ... )--ISIN XS0179021133 Issuer Name GREENLAND CDO LTD Paying Agent HSBC BANK PLC Redemption Type REPURCHASE Currency EUR O/S Balance 244,020,000.00 New Balance 0 .0... )--FUND A db x-trackers MSCI JAPAN TRN INDEX UCITS ETF DEALING DATE A 15-Jul-14 NAV PER SHARE A USD47.7014 ... (more)
Mon Jul 14, 2014
Is Bristol-Myers Squibb Overvalued?
Bristol-Myers's stock price has been lowered by analysts but they still expect the future price to be above the current price of the stock.
Thu Jul 10, 2014
Bristol-Myers Squibb Makes Plans to Submit Biologics License Application for OpdivoA
Bristol-Myers Squibb Company today announced that, following discussions with the U.S. Food and Drug Administration , the company is planning a third quarter submission of a Biologics Licensing Application for OpdivoA for previously treated advanced melanoma.
Book trade news from Book2book
Bloomsbury Publishing 3-month Revenues Down 9%
Bloomsbury Publishing Plc reported that in the three months ended 31 May 2014, total revenues were down by 9% on last year , but are up by 7% when compared to the three months ended 31 May 2012.
HIV and Hepatitis
Interferon-free Daclatasvir + Asunaprevir Approved in Japan for Hepatitis C
Bristol-Myers Squibb's all-oral dual regimen of daclatasvir plus asunaprevir has been approved for the treatment of chronic hepatitis C in Japan, where most people are infected with HCV genotype 1b, the company announced this week.
Tue Jul 08, 2014
Bristol-Myers Squibb Given New $55.00 Price Target at Leerink Swann
Leerink Swann's price objective would suggest a potential upside of 14.92% from the stock's previous close.